XTL Biopharmaceuticals Ltd. (XTLB)
XTLB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1023549/000121390025037590/0001213900-25-037590-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | XTLB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001023549 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $451K |
| Net income | -$1.0M |
| Operating income | -$2.2M |
| Net margin | -227.7% |
| Operating margin | -481.6% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $371K |
| Total assets | $8.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 8.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1: GENERAL (Cont.) These factors, individually and in the aggregate, raise substantial doubt about the Company's ability to continue as a going concern." | 20-F 2026-06-30 |
| Cash and burn | $76K cash; operating cash flow -$256K a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-4 on 2026-03-25 | Source 2026-03-25 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Barzily&Co Certified Public Accountants, Jerusalem, Israel | PCAOB Form AP 2026-07-02 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-04-30 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$7.0M | -$1.0M | $76K | No debt tags | Needs four quarters | 20-F 2026-06-30 |
| FY 2024 2024-12-31 | $451K | -$1.0M | -$1.6M | $371K | $138K | $451K | 20-F 2025-04-30 |
| FY 2023 2023-12-31 | Not filed | -$1.8M | -$707K | $1.4M | No debt tags | Needs four quarters | 20-F 2025-04-30 |
| FY 2022 2022-12-31 | Not filed | -$1.3M | -$901K | $2.1M | No debt tags | Needs four quarters | 20-F 2025-04-30 |
| FY 2021 2021-12-31 | Not filed | $435K | -$1.0M | $3.0M | No debt tags | Needs four quarters | 20-F 2023-03-22 |
| FY 2020 2020-12-31 | Not filed | -$3.0M | -$850K | $3.6M | No debt tags | Needs four quarters | 20-F 2023-03-22 |
| FY 2019 2019-12-31 | Not filed | -$763K | -$908K | $4.5M | No debt tags | Needs four quarters | 20-F 2022-03-30 |
| FY 2018 2018-12-31 | Not filed | $3.6M | -$816K | $3.3M | No debt tags | Needs four quarters | 20-F/A 2021-05-19 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B3 | 2021-06-09 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-06-30 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-10-14 |
Source: SEC EDGAR submissions feed, 546 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.2% |
| 1 month | -19.2% |
| 3 months | -42.9% |
| Year to date | -31.0% |
| 1 year | -57.4% |
| From 52-week high | -62.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AZTR | Azitra Inc | $0.6270 | +3.06% | $3.8M |
| GELS | Gelteq Limited | $0.3589 | -5.63% | $3.8M |
| IMNN | Imunon Inc. | $0.5940 | -5.56% | $3.9M |
| TRAW | Traws Pharma Inc. | $0.2600 | +3.59% | $4.0M |
| XBIO | Xenetic Biosciences Inc. | $1.49 | -10.24% | $3.5M |
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
| BGMS | Bio Green Med Solution Inc. | $0.6502 | +1.55% | $4.3M |
| KPRX | Kiora Pharmaceuticals Inc. | $0.9820 | -20.16% | $4.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier